1 completed, 1 terminated, 1 withdrawn. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Bioniche Life Sciences Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer EN3348, Mitomycin C - Bladder Neoplasm, Neoplasm Recurrence, Local | Phase 3 | Terminated | Bioniche Life Sciences Inc. | 84 | 2010-11-01 | 2017-08-24 |
| First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC Mycobacterial Cell-Wall DNA Complex, Bacillus Calmette-Guerin - Bladder Cancer | Phase 3 | Withdrawn | Bioniche Life Sciences Inc. | 2010-01-01 | 2014-08-29 | |
| Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Mycobacterial cell wall-DNA complex - Bladder Neoplasms | Phase 2 / Phase 3 | Completed | Bioniche Life Sciences Inc. | 129 | 2006-11-01 | 2016-07-28 |
Urinary Bladder Neoplasms (3) · Carcinoma in Situ (2) · Carcinoma, Transitional Cell (2) · Mycobacterium Infections (2) · Neoplasm Recurrence, Local (2) · Neoplasms (1) · Neoplasms by Site (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Urinary Bladder Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1) · Urologic Neoplasms (1)
BCG Vaccine (1) · Mitomycin (1)
United States (3) · Canada (2) · Germany (1) · Netherlands (1) · Poland (1) · United Kingdom (1)